Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2004.05.009 on June 1 2004

Journal of Clinical Oncology, Vol 22, No 13 (July 1), 2004: pp. 2554-2566
© 2004 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mandelblatt, J. S.
Right arrow Articles by Fahs, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mandelblatt, J. S.
Right arrow Articles by Fahs, M.
Related Articles
Right arrowRelated Editorial
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Benefits and Costs of Interventions to Improve Breast Cancer Outcomes in African American Women

Jeanne S. Mandelblatt, Clyde B. Schechter, K. Robin Yabroff, William Lawrence, James Dignam, Peter Muennig, Yoko Chavez, Jennifer Cullen, Marianne Fahs

From the Department of Oncology, Georgetown University Medical Center, and Cancer Control Program, Lombardi Cancer Center, Washington, DC; Department of Family Medicine, Albert Einstein School of Medicine, Bronx; City University of New York, New York; Health Policy Research Center at the Robert J. Milano Graduate School of Management and Urban Policy at the New School for Social Research, New York, NY; and the Department of Health Studies and University of Chicago Cancer Research Center, University of Chicago, Chicago, IL

Address reprint requests to Jeanne Mandelblatt, MD, MPH, Lombardi Cancer Center, 2233 Wisconsin Ave, Suite 317, Washington, DC 20007; e-mail: mandelbj{at}georgetown.edu

PURPOSE: Historically, African American women have experienced higher breast cancer mortality than white women, despite lower incidence. Our objective was to evaluate whether costs of increasing rates of screening or application of intensive treatment will be off-set by survival benefits for African American women.

METHODS: We use a stochastic simulation model of the natural history of breast cancer to evaluate the incremental societal costs and benefits of status quo versus targeted biennial screening or treatment improvements among African Americans 40 years of age and older. Main outcome measures were number of mammograms, stage, all-cause mortality, and discounted costs per life year saved (LYS).

RESULTS: At the current screening rate of 76%, there is little incremental benefit associated with further increasing screening, and the costs are high: $124,053 and $124,217 per LYS for lay health worker and patient reminder interventions, respectively, compared with the status quo. Using reminders would cost $51,537 per LYS if targeted to virtually unscreened women or $78,130 per LYS if targeted to women with a two-fold increase in baseline risk. If all patients received the most intensive treatment recommended, costs increase but deaths decrease, for a cost of $52,678 per LYS. Investments of up to $6,000 per breast cancer patient could be used to enhance treatment and still yield cost-effectiveness ratios of less than $75,000 per LYS.

CONCLUSION: Except in pockets of unscreened or high-risk women, further investments in interventions to increase screening are unlikely to be an efficient use of resources. Ensuring that African American women receive intensive treatment seems to be the most cost-effective approach to decreasing the disproportionate mortality experienced by this population.

Supported by grants K05 CA96940 (J.S.M.) and RO1 CA72908 (J.S.M., K.R.Y., C.B.S., P.M., and M.F.) and cooperative agreement No. UO1-CA88293A from the National Cancer Institute (J.S.M., K.R.Y.,W.L., C.B.S., J.C., Y.C., and J.D.), Bethesda, MD.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Editorial

  • An Ounce of Prevention or a Pound of Cure? Investing to Improve Breast Cancer Outcomes for African American Women
    Hannah M. Linden, Scott Ramsey, and Nancy Anderson
    JCO 2004 22: 2517-2518 [Full Text]


This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. H. Ahern and Y. Shen
Cost-Effectiveness Analysis of Mammography and Clinical Breast Examination Strategies: A Comparison with Current Guidelines
Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 718 - 725.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. S. Mandelblatt, J. Cullen, W. F. Lawrence, A. L. Stanton, B. Yi, L. Kwan, and P. A. Ganz
Economic Evaluation Alongside a Clinical Trial of Psycho-Educational Interventions to Improve Adjustment to Survivorship Among Patients With Breast Cancer
J. Clin. Oncol., April 1, 2008; 26(10): 1684 - 1690.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
N. K. Stout, M. A. Rosenberg, A. Trentham-Dietz, M. A. Smith, S. M. Robinson, and D. G. Fryback
Retrospective cost-effectiveness analysis of screening mammography.
J Natl Cancer Inst, June 7, 2006; 98(11): 774 - 782.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. J. Blackman and C. M. Masi
Racial and Ethnic Disparities in Breast Cancer Mortality: Are We Doing Enough to Address the Root Causes?
J. Clin. Oncol., May 10, 2006; 24(14): 2170 - 2178.
[Abstract] [Full Text] [PDF]


Home page
J Natl Cancer Inst MonogrHome page
T. S. Field, D. S. M. Buist, C. Doubeni, S. Enger, H. Fouayzi, G. Hart, E. J. Korner, L. Lamerato, D. J. Bachman, J. Ellis, et al.
Disparities and Survival Among Breast Cancer Patients
J Natl Cancer Inst Monographs, November 1, 2005; 2005(35): 88 - 95.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. J. DeNardo, C. M. Richman, H. Albrecht, P. A. Burke, A. Natarajan, A. Yuan, J. P. Gregg, R.T. O'Donnell, and G. L. DeNardo
Enhancement of the Therapeutic Index: From Nonmyeloablative and Myeloablative toward Pretargeted Radioimmunotherapy for Metastatic Prostate Cancer
Clin. Cancer Res., October 1, 2005; 11(19): 7187s - 7194s.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. Hershman, R. McBride, J. S. Jacobson, L. Lamerato, K. Roberts, V. R. Grann, and A. I. Neugut
Racial Disparities in Treatment and Survival Among Women With Early-Stage Breast Cancer
J. Clin. Oncol., September 20, 2005; 23(27): 6639 - 6646.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
H. M. Linden, S. Ramsey, and N. Anderson
An Ounce of Prevention or a Pound of Cure? Investing to Improve Breast Cancer Outcomes for African American Women
J. Clin. Oncol., July 1, 2004; 22(13): 2517 - 2518.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2004 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online